Ergoteles’s Takeda Pharmaceutical TAK Stock Holding History

Ergoteles’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,540	Closed	-$294K	–	1991
2022 Q1	$294K	Buy	+20,540	New	+$302K	0.01%	846

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ergoteles's TAK Position: Q2 2022 in Review

Ergoteles sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 20,540 shares — an estimated $294K sold.

Ergoteles first reported a position in TAK in Q1 2022 and held it in 1 quarter. The position peaked at $294K in Q1 2022. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Ergoteles reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Ergoteles sold 20,540 Takeda Pharmaceutical shares in Q2 2022, an estimated $294K.
Ergoteles first reported a position in Takeda Pharmaceutical in Q1 2022 and held it in 1 quarter.
Ergoteles's Takeda Pharmaceutical position peaked at $294K in Q1 2022.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.